Business Description
WuXi Biologics (Cayman) Inc
ISIN : KYG970081090
Share Class Description:
HKSE:02269: Registered Shs Unitary 144A/Reg SCompare
Compare
Traded in other countries / regions
02269.Hong KongWXXWY.USA1FW2.Germany2269.Mexico IPO Date
2017-06-13Description
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.47 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | 1.05 | |||||
| Interest Coverage | 28.08 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.04 | |||||
| Beneish M-Score | -2.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 52 | |||||
| 3-Year EBITDA Growth Rate | 60.9 | |||||
| 3-Year EPS without NRI Growth Rate | 55.8 | |||||
| 3-Year FCF Growth Rate | 47.2 | |||||
| 3-Year Book Growth Rate | 36.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 14.98 | |||||
| Future 3-5Y Total Revenue Growth Rate | 14.4 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.93 | |||||
| 9-Day RSI | 35.08 | |||||
| 14-Day RSI | 36.79 | |||||
| 6-1 Month Momentum % | -69.29 | |||||
| 12-1 Month Momentum % | -69.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.78 | |||||
| Quick Ratio | 2.54 | |||||
| Cash Ratio | 1.47 | |||||
| Days Inventory | 72.23 | |||||
| Days Sales Outstanding | 108.98 | |||||
| Days Payable | 26.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.9 | |||||
| Shareholder Yield % | 4.22 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40.08 | |||||
| Operating Margin % | 26.13 | |||||
| Net Margin % | 19.96 | |||||
| FCF Margin % | 6.54 | |||||
| ROE % | 8.96 | |||||
| ROA % | 6.4 | |||||
| ROIC % | 9.42 | |||||
| ROC (Joel Greenblatt) % | 14.37 | |||||
| ROCE % | 9.7 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.23 | |||||
| Forward PE Ratio | 11.65 | |||||
| PE Ratio without NRI | 12.98 | |||||
| Price-to-Owner-Earnings | 54.09 | |||||
| PEG Ratio | 0.2 | |||||
| PS Ratio | 2.99 | |||||
| PB Ratio | 1.24 | |||||
| Price-to-Tangible-Book | 1.29 | |||||
| Price-to-Free-Cash-Flow | 45.95 | |||||
| Price-to-Operating-Cash-Flow | 7.38 | |||||
| EV-to-EBIT | 9.81 | |||||
| EV-to-Forward-EBIT | 8.99 | |||||
| EV-to-EBITDA | 9.81 | |||||
| EV-to-Forward-EBITDA | 7.35 | |||||
| EV-to-Revenue | 2.49 | |||||
| EV-to-Forward-Revenue | 2.37 | |||||
| EV-to-FCF | 38.14 | |||||
| Price-to-Projected-FCF | 18.2 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.4 | |||||
| Price-to-Graham-Number | 0.86 | |||||
| Price-to-Net-Current-Asset-Value | 10.03 | |||||
| Earnings Yield (Greenblatt) % | 10.19 | |||||
| FCF Yield % | 2.28 | |||||
| Forward Rate of Return (Yacktman) % | 15.98 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
WuXi Biologics (Cayman) Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 18,631.723 | ||
| EPS (TTM) (HK$) | 0.842 | ||
| Beta | 1.42 | ||
| Volatility % | 52.03 | ||
| 14-Day RSI | 36.79 | ||
| 14-Day ATR (HK$) | 0.864578 | ||
| 20-Day SMA (HK$) | 13.563 | ||
| 12-1 Month Momentum % | -69.72 | ||
| 52-Week Range (HK$) | 12.42 - 52.45 | ||
| Shares Outstanding (Mil) | 4,162.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
WuXi Biologics (Cayman) Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
WuXi Biologics (Cayman) Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
WuXi Biologics (Cayman) Inc Frequently Asked Questions
What is WuXi Biologics (Cayman) Inc(HKSE:02269)'s stock price today?
The current price of HKSE:02269 is HK$12.74. The 52 week high of HKSE:02269 is HK$52.45 and 52 week low is HK$12.42.
When is next earnings date of WuXi Biologics (Cayman) Inc(HKSE:02269)?
The next earnings date of WuXi Biologics (Cayman) Inc(HKSE:02269) is 2024-08-23 Est..
Does WuXi Biologics (Cayman) Inc(HKSE:02269) pay dividends? If so, how much?
WuXi Biologics (Cayman) Inc(HKSE:02269) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers